Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, Carrieri V, Albano O
Continued tissue remodeling
FDA labeling for EGRIFTA WR states that tesamorelin is indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, while also noting that it is not indicated for weight-loss management and that long-term cardiovascular safety has not been established. For a research comparison article, Tesamorelin gives useful context: it shows that the GHRH analog category is not limited to CJC-1295 and Sermorelin
The Effect of GLP-1 on Gastric Emptying in Humans
When compared to the placebo group, PBMCs isolated from individuals with T2DM who received L-GSH supplementation for 3-months had a significantly reduced burden of BCG ( Figure 6A )
The candidate is currently in Phase IIb development